Cross-reactivity of skin rashes with current antiepileptic drugs in Chinese population  by Wang, Xiang-qing et al.
Seizure 19 (2010) 562–566Cross-reactivity of skin rashes with current antiepileptic drugs in
Chinese population
Xiang-qing Wang *, Sen-yang Lang, Xiao-bin Shi, Hui-jun Tian, Rong-fei Wang, Fei Yang
Department of Neurology, PLA General Hospital, Beijing 100853, China
A R T I C L E I N F O
Article history:
Received 7 June 2010
Received in revised form 1 August 2010







A B S T R A C T
Objective: Due to less experience with the cross-reactivity of antiepileptic drugs (AEDs) in Chinese
population, we surveyed the rates of cross- reactivity of rash among commonly used AEDs in Chinese
patients with epilepsy, particularly between the traditional and the new compounds.
Methods: We have retrospectively reviewed the medical records concerning all antiepileptic drug
treatment in consecutive Chinese patients with epilepsy in our center. The incidence of AED-related rash
was determined in 3793 outpatients, taking at least one of the AEDs-carbamazepine (CBZ), valproic acid
(VPA), phenytoin (PHT), phenobarbital (PB), clonazepam (CZP), oxcarbazepine (OXC), lamotrigine (LTG),
gabapentin (GBP), topiramate (TPM), levetiracetam (LEV) and traditional Chinese medicine (TCM). We
have performed telephone interviews among all patients with AEDs-related rash. We described the
clinical characteristics of the 18 patients with cross-reactivity involving the AEDs, and the cross-
reactivity pattern for CBZ, PHT, OXC, and LTG.
Results: A total of 3.61% (137/3793) of patients experienced a skin rash to at least one AEDs, of these
patients, 73 (53.28%) were female and 64 were males (46.72%). While 18 patients had a rash to two or
more AEDs. Of patients who had a rash to CBZ and were also prescribed PHT (n = 17), 52.9% had a rash to
PHT (abbreviated as CBZ! PHT: 52.9%); of patients who had a rash to PHT and were also prescribed CBZ
(n = 13), rate of rash was 69.2% (i.e., PHT! CBZ: 69.2%). Other results: CBZ! LTG: 25% (n = 16); LTG
! CBZ: 44.4% (n = 9); CBZ! OXC: 40% (n = 10); OXC! CBZ: 66.7% (n = 6); LTG! PHT: 20% (n = 5);
PHT! LTG: 16.7% (n = 6); OXC! LTG: 25% (n = 4); LTG! OXC: 33.3% (n = 3); OXC! PHT: 25% (n = 4);
PHT! OXC: 16.7% (n = 6). There was a highly signiﬁcant mutual risk for cross- reactivity for CBZ and
PHT, andOXC, and LTG (p < 0.001), mutual risk reached statistical signiﬁcance for LTG and CBZ (p = 0.01).
Conclusion: Cross-reactivity rates between certain AEDs are high, especially when involving
carbamazepine and phenytoin. There were also too few patients with rash to reach deﬁnitely
conclusions about possible cross-reactivity. Larger numbers of patients would be needed to assess this
and the mechanism. Caution should be exercised when prescribing certain AEDs (especially CBZ and
PHT, but also OXC, and LTG).
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a serious chronic brain disorder that is characterized
by recurrent unprovoked seizures, which in most patients can be
successfully treated and controlled with mono- or polytherapy.
Rash is a common side effect of antiepileptic drugs (AEDs).1–3 The
rash is most commonly a benign exanthematous eruption, which
disappeared within a few days after discontinuation of the drug;
however, severe life threatening reactions could occur, such as
Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis
(TEN)4–7 (characterized by focal or extensive detachment of
epidermis and erosions of mucous membranes), and hypersensi-* Corresponding author. Tel.: +86 13661018488.
E-mail address: bjxqwang@yahoo.com.cn (X.-q. Wang).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.09.003tivity syndrome8,9 (characterized by fever, skin rash, and systemic
manifestations such as hepatitis and eosinophilia). Benign rash are
relatively common with aromatic AEDs (such as phenytoin,
carbamazepine, and phenobarbital) with a frequency ranging
from 5 to 15% of treated individuals.1 The relatively new
antiepileptic drug oxcarbazepine and lamotrigine are also reported
to cause skin rash. Although lamotrigine has a different structure, it
has also been frequently associated to rash (8–10%).10 A high
starting dose and a rapid dose escalation have been identiﬁed as
risk factors, especially for LTG, particularly when its metabolism is
inhibited by valproate, and can be reduced with low doses and
slow titration. Cross sensitivity among aromatic AEDs occurs in
40–58% of patients11,12 in vivo and has been reported as high as
80% in an in vitro assay.13 A rechallenge with a possible cross-
reactive AED resulted in hypersensitivity reactions in up to 87% of
patients.14vier Ltd. All rights reserved.
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Fig. 1. Diagram of drugs causing skin rash. CBZ: carbamazepine, VPA: valproic acid,
PHT: phenytoin, PB: Phenobarbital, CZP: clonazepam, OXC: oxcarbazepine, LTG:
lamotrigine, TPM: topiramate, LEV: levetiracetam, and TCM: traditional Chinese
medicine.
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rashes amonga largenumberofpatients takingmore thanoneAEDs.
There is less experiencewith the cross-reactivity of AEDs in Chinese
population. The aim of this study was to assess cross-reactivity of
skin rashes among current AEDs, including new generation of
antiepileptic drugs (OXC and LTG) in Chinese population.
2. Methods
We systematically reviewed the medical records of 3793
consecutive outpatients with epilepsy taking at least one antiepi-
leptic drugs, seen by at least two epileptologists at the Epilepsy
Center of PLA General Hospital between February 25,1999, and
April 9, 2010. A cutaneous side reactionwas deﬁned as any types of
rash, no other obvious reason than an antiepileptic drug effect,
which only has itching feeling without obvious skin change was
excluded. We recorded the clinical description of rashes and all
drugs using in all patients. We have performed telephone
interviews among all patients with AEDs related-rash and some
no rash patients who’s documentationwas considered insufﬁcient.
All patients had at least one ofﬁce visit or telephone interviews
after the occurrence of skin reaction.
We compared the rate of rash attributed to the 11 most
commonly used AEDs at our center: carbamazepine (CBZ), valproic
acid (VPA), phenytoin (PHT), phenobarbital (PB), clonazepam
(CZP), oxcarbazepine (OXC), lamotrigine (LTG), gabapentin (GBP),
topiramate (TPM), levetiracetam (LEV) and traditional Chinese
medicine (TCM). Cross-reaction was deﬁned as sequential rashes
from different AEDs in the same individual.
Data were analyzed using SPSS v.13.0. X2 or Fisher exact tests
were used as applicable, to compare the rates of rash to speciﬁc
AEDs in patients with and without rash to other speciﬁc AEDs.
Signiﬁcance was set at p < 0.001, and p value between 0.001 and
0.05 was considered a trend.
3. Results
Overall, 3.61% (137/3793) of patients experienced a skin rash to
at least one AEDs, while 13.14% (18/137) patients had a rash to two
or more AEDs. As much as 75% of the reactions occurred either to
CBZ (42.34%, 58 of 137), LTG (16.79%, 23 of 137), OXC (10.95%, 15 of
137), or PHT (5.11%, 7 of 137) (Fig. 1). Of these patients, 64 were
males (46.72%) and 73 (53.28%) were female. Females (4.97%, 73/Table 1
Clinical characteristic of patients with rash from more than one antiepileptic drugs.
Patient Sex Age First rash Second rash
1 M 18 CBZ PHT
2 M 50 CBZ PHT
3 F 6 CBZ LTG
4 F 8 OXC LTG
5 F 28 CBZ PHT
6 F 30 CBZ PHT
7 F 58 CBZ PHT
8 M 15 CBZ TPM
9 F 16 CBZ LTG
10 F 27 CBZ OXC
11 F 18 LTG VPA
12 F 40 CBZ LTG
13 M 21 CBZ PHT
14 M 35 CBZ OXC
15 Ma 41 CBZ PHT
16 Ma 70 CBZ PHT
17 F 39 CBZ LTG
18 Fa 41 CBZ OXC
The column to the right shows other drugs used for more than 3 months without causin
OXC: oxcarbazepine, LTG: lamotrigine, GBP: gabapentin, TPM: topiramate, LEV: levetir
a Stevens–Johnson syndrome.1470) were nearly twice as likely to develop a rash as were males
(2.76%, 64/2323) (OR = 1.84, CI 1.31–2.60, p < 0.001). Most
patients (83.94%, 115/137) had common maculopapular eruption.
92.70% (127/137) rashes occurred less than three mouths after
beginning medication.
18 patients experienced more than one AEDs, of whom 11
(61.11%) were females. Clinical characteristics of the 18 patients
with cross-reactivity involving the AEDs were showed in Table 1.
Five patients experienced skin reactions from more than two
drugs. Three subjects reported Stevens–Johnson syndrome, all of
them were related to CBZ-SJS. A 41-year-old man had been on
medication of CBZ (400 mg daily) for 1 year without rash, however,
dyspnea and palpitation occurred after he received antibiotics for
inﬂuenza. Two months later, the dose of CBZ was increased to
600 mg daily for poor control of epilepsy and skin rash with focal
detachment of epidermis (SJS) occurred seven days later. Another
70-year-old man suffered with maculopapular rash and focal
detachment of epidermis (SJS) after he had taken CBZ (400 mg
daily) for one month. CBZ was then discontinued. Six months later,
PHT (300 mg daily) was administered and rash occurred again.
Now he is on medication of TPM without any adverse effects. In a


















g rash. CBZ: carbamazepine, VPA: valproic acid, PHT: phenytoin, PB: phenobarbital,
acetam, and TCM: traditional Chinese medicine.
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Fig. 2. Cross- reactivity pattern for CBZ (a), PHT (b), OXC (c), and LTG (d). The white
columns represent the rash frequency in patients without reactions to the indicated
drug, whereas the black columns represent the cross-reactivity rate [e.g. the ﬁrst
bar set represents the following: 58/1908 without rash from PHT (unexposed or
exposed) experienced a rash from CBZ, and 9/11 patients with rash from PHT also
experienced a rash from CBZ].
X.-q. Wang et al. / Seizure 19 (2010) 562–566564(300 mg daily) for one month. However, CBZ was not stoped, the
rash aggravated, SJS developed and oralmucosawas afﬂicted seven
days later. The rash resolved after CBZ was discontinued. Three
months later, OXC (150 mg daily) was administered and sporadic
maculopaular rash reoccurred in face the second day after the
medication. OXC was discontinued and the rash resolved, SJS did
not occur.
4. Rash cross-reactions rates
The pattern of cross-reactivity is illustrated by bar charts in
Fig. 2. Cross-reactions results are studied and abbreviated by thefollowing nomenclature (as an example, to report the rates of
cross-reactions between CBZ and PHT): Of patients who had a rash
to CBZ and were also prescribed PHT (n = 17), 52.94% (9/17) had a
rash to PHT (abbreviated CBZ! PHT: 52.94%); of patients who had
a rash to PHT and were also prescribed CBZ (n = 13), rate of rash
was 69.2% (i.e., PHT! CBZ: 69.2%). Other results: CBZ! LTG: 25%
(n = 16); LTG! CBZ: 44.4% (n = 9); CBZ! OXC: 40% (n = 10);
OXC! CBZ: 66.7% (n = 6); LTG! PHT: 20% (n = 5); PHT! LTG:
16.7% (n = 6); OXC! LTG: 25% (n = 4); LTG! OXC: 33.3% (n = 3);
OXC! PHT: 25% (n = 4); PHT! OXC: 16.7% (n = 6). It should be
pay attention to that the two cross-reactivity rates for each AED
pair (CBZ! PHT and PHT! CBZ, for example), does not imply that
one drug was prescribed before another, but simply that there was
a rash to the ﬁrst drug, and the second drug was also prescribed
(either before of after). There was evidence of speciﬁc cross-
reaction between CBZ and PHT, and between PHT and CBZ, and
between CBZ and OXC, and between CBZ and LTG (p < 0.001), with
a trend between LTG and CBZ (p = 0.01). For example, the CBZ rash
rate in patients who also had a rash to PHT (81.81%) was
signiﬁcantly higher compared to without rash from PHT (unex-
posed or exposed) experienced a rash from CBZ (3.04%). Numbers
with PHT, OXC and LTG were too small to reach any meaningful
conclusions. Fig. 3 shows detailed data of skin reactions and drug
exposures.
5. Discussion
Our result showed 3.61% of patients experienced a skin rash to
at least one AEDs, while 18 (13.14%) patients had a rash to two or
more AEDs. Carbamazepine (42.34%) was the leading cause of
AEDs-rash in our study, followed by lamotrigine, oxcarbazepine,
and phenytoin. They usually occur as mild and monosymptomatic
maculopapulous exanthemas and only require withdrawal of the
offending drugs for resolution. Three subjects reported Stevens–
Johnson syndrome, all of them were related to CBZ-SJS, no fatal
cutaneous adverse reactions occurred.
Cross-reaction among aromatic AEDs (CBZ, LTG, OXC, PHT, PB)
is said to occur in 40–58% of patients. Handoko et al.15 found that
symptoms of hypersensitivity were reported twice as frequently
with aromatic AEDs than with non-aromatic AEDs. Our results are
generally consistent with these ﬁndings, but expand upon them in
a larger population (n = 3793, but only 18 patients having rash to
more than one AED) and involvingmore AEDs, including the newer
ones. On average one in six of our patients who presented with a
rash from one of the high risk drugs (CBZ, PHT, OXC and LTG) also
developed a rash when exposed to another. Alvestad et al.16 have
retrospective reviewed of 663 patients with epilepsy, skin
reactions occurred in 93 patients and sequential rashes related
to aromatic drugs in 17 patients. A history of an AED-related rash
was signiﬁcantly associated with reactions to PHT, CBZ, and OXC
(p < 0.001). The associationwas only borderline signiﬁcant for LTG
(p = 0.05). The largest previously publisher report17 on cross-
reactivity between several AEDs was a retrospective review of
1875 outpatients (2 years) exposures to 15 AEDs, 72 of the 1875
(2.8%) patients had a rash to two or more AEDs. Of patients who
had a rash to CBZ and were also prescribed PHT (n = 59), 57.6% had
a rash to PHT; of patients who had a rash to PHT and were also
prescribed CBZ (n = 81), rate of rash was 42.0%. These results are
comparable to ours (CBZ! PHT: 52.94%, PHT! CBZ: 69.2%,
respectively).
PHT and CBZ are the two drugs which most frequently cause
mutual sensitivity. In this study it occurred with similar rates (50–
69%) as in the previous study by Hyson and Sadler12 (40–58%). We
also found a highly signiﬁcant mutual risk for cross-reaction for
CBZ, PHT, OXC, and LTG (p < 0.001), mutual risk reached statistical
signiﬁcance for LTG and CBZ (p = 0.01). OXC has less potential to
[(Fig._3)TD$FIG]
Fig. 3. Venn diagram showing numerical data of cross-reactivity among antiepileptic drugs. The p values compare rash rates for each drug in patients exposed to two drugs
with and without rash from the other.
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differentmetabolic pathway. But the somewhat higher frequency of
OXC-related rash in our patients, 8.92%, compared to ﬁndings
derived from controlled clinical studies (3%).19 Cross-sensitivities in
patients with known rashes from CBZ have been found in the range
of 25–31%,16 our result (40–67%) higher than that (Fig. 3), but there
were also too few patients to reach deﬁnitely conclusions.
Speciﬁc cross- reactivity among CBZ, PHT, and OXC may be at
least partially explained by the ‘‘hapten hypothesis’’20 that suggests
commonmetabolic and immunologic pathway responsible for rash
to there AEDs. CBZ, PHT, and PB are metabolized to arene oxide
metabolitesbyhepaticcytochromeP450enzymes. There isevidence
the CBZ-speciﬁc T-cells may exist in peripheral blood of hypersen-
sitive patients many years after resolution of clinical symptoms.21
Nevertheless, in the last decade, ﬁndings from in vitro studies have
challenged the classic ‘‘hapten hypothesis’’ by demonstrating that
the parent drugs CBZ, PHT, and PBmay stimulate T-cell clones even
in the absence of any apparent reactive metabolite formation.22,23
Recently, a strong association was found between Stevens–Johnson
syndrome and the HLA B*1502 gene in Han Chinese treated withCBZ.24 Therefore, to identify genetic polymorphisms predisposing
may offer the possibility of avoiding the development of AED-
induced severe cutaneous reaction inChinesepatientswith epilepsy
in the further study.
Our data also show highly signiﬁcant mutual risk for cross-
reactivity rates between CBZ and LTG, these ﬁndings are different
with other studies which showed lower rash cross- reactivity rates
with other AEDs for LTG than for the other aromatic AEDs.16
Chemically, LTG is also an aromatic compound with two ring
structures. LTG can be bioactivated to an arene oxide. It has been
hypothesized that this may represent a minor metabolic pathway
in humans, which may cause rash. There is evidence that LTG may
directly stimulate T-cells in the absence of any apparent hapten
formation or antigen processing.25 Few studies have assessed
immunologic cross-reactivity and their results are contradictory.26
The mechanisms behind skin reactions and cross-reactivity
indeed appear to be complex and diverse. In our study, there were
also too few patients with rash to reach deﬁnitely conclusions
about possible cross-reactivity. Larger numbers of patients would
be needed to assess this and the mechanism.
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This study is based on a retrospective analysis, which is the
major limitation of it, including a remote history of only vaguely
described rashes. Our retrospective approach and the small
number of patients in some of the subgroups are apparent
weaknesses in this study. Not every rash was examined by a
physician. There may have physician bias in making the
determination of whether a certain rash was related to a given
medication. Recall bias about AED treatment initiated prior to
treatment at our center may have resulted in underreporting of
prior AED-related rashes in some patients, particularly the old
medications (phenobarbital) used decades ago. Some individuals
medical records may have been incomplete, but the study was
carried out at specialist outpatient clinics served by the same
specialists. In our hospital, epilepsy is traditionally treated and
followed up by hospital specialists and detailed medical records
were available for most patients back to our outpatient depart-
ment or by telephone interviews. Treatment selection bias may
have served to equalize individual AED-rash rates patients with a
documented history of AED-rashmay preferentially be prescribed
AEDs less often associated with rash (e.g., LEV, GBP, TPM, or VPA).
7. Conclusion
To the best of our knowledge, our study is the ﬁrst one that
demonstrated the rates of cross- reactivity of rash among commonly
used AEDs in Chinese patients with epilepsy. Cross- reactivity rates
between certain AEDs are high, especially when involving carba-
mazepine andphenytoin. In this study, the cross-reactivity between
LTG and the other aromatic AEDs (PHT, andCBZ)was not lower than
other aromatic drugs. But therewere also too fewpatientswith rash
to reach deﬁnitely conclusions about possible cross-reactivity.
Larger numbers of patients would be needed to assess this and the
mechanism. Caution should be exercised when prescribing certain
AEDs (especially CBZ and PHT, but also OXC, and LTG).
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